Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
16 déc. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the submission of an sNDA to the FDA for ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 for mild to moderate AD.
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
13 nov. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Dermatology Treatment and Care Research Report 2024-2030 with Analyst Recommendations - Tapping into the Demand for Tailored Solutions / Focus on Expansion in Emerging Markets
29 oct. 2024 05h01 HE
|
Research and Markets
Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatology Treatment and Care Market (2024 Edition): Analysis By Treatment Type (Skin Disease and Care, Hair Disease and Care), By Route of...
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
24 oct. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients and families.
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
25 sept. 2024 01h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
09 sept. 2024 10h20 HE
|
Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
U.S. Dermatology Imaging Devices Market Report 2024-2030: Digital Photographic Imaging, OCT, Dermatoscope, Skin Cancers, Inflammatory Dermatoses Size, Share & Trends Analysis
09 sept. 2024 07h34 HE
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "U.S. Dermatology Imaging Devices Market Size, Share & Trends Analysis Report By Modality (Digital Photographic Imaging, OCT, Dermatoscope), By...
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
28 août 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
29 juil. 2024 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22 juil. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis will host a KOL virtual event July 29, 2024